Treatment-Resistant Depression: Augmentation Strategies and Emerging Therapies

Defining Treatment-Resistant Depression

Every psychiatrist and primary care physician who manages depression has patients for whom standard antidepressant therapy simply does not work. The patient who has tried sertraline, then switched to venlafaxine, then added bupropion — and remains functionally impaired with persistent depressive symptoms — is not an outlier. This patient represents roughly one-third of all individuals diagnosed with major depressive disorder. Treatment-resistant depression is not rare. It is the expected outcome for a significant minority of patients, and having a systematic approach to augmentation and alternative therapies is essential for any clinician who prescribes antidepressants.

Treatment-resistant depression (TRD) is generally defined as failure to achieve adequate response after two or more adequate trials of antidepressant therapy. The STAR*D trial demonstrated that with each successive treatment step, remission rates decline from 37% (Step 1) to 13% (Step 4), underscoring the clinical challenge of TRD management. For adolescent-specific considerations, see our review of adolescent depression.

Before Calling It Treatment-Resistant

Before escalating to augmentation strategies, the clinician should confirm that prior trials were truly adequate. An adequate trial means a therapeutic dose maintained for at least 6-8 weeks with verified adherence. In practice, many patients labeled as treatment-resistant have actually received subtherapeutic doses, inadequate durations, or have had adherence gaps that were never identified. A careful medication history — asking specifically about the maximum dose reached, how long it was maintained, and whether the patient took the medication consistently — can sometimes reveal that what appears to be treatment resistance is actually undertreated depression. Additionally, comorbid conditions that undermine antidepressant efficacy should be identified and addressed: untreated hypothyroidism, substance use disorders, obstructive sleep apnea, and chronic pain all reduce the likelihood of antidepressant response and should be managed concurrently.

Lithium Augmentation: The Classical Approach

Lithium augmentation of antidepressant therapy remains the best-studied augmentation strategy with the strongest evidence base. Target serum levels of 0.6-0.8 mEq/L provide optimal efficacy with acceptable tolerability. Meta-analyses show lithium augmentation achieves response in approximately 40-50% of TRD patients.

Why Lithium Remains Underused

Despite the strongest evidence base of any augmentation strategy, lithium is prescribed far less frequently than atypical antipsychotic augmentation in current practice. The reasons are largely practical rather than scientific: lithium requires serum level monitoring, has a narrow therapeutic window, interacts with common medications (NSAIDs, ACE inhibitors, thiazide diuretics), and carries risks of renal and thyroid toxicity with long-term use. These are real concerns, but they are manageable — and the evidence supporting lithium augmentation is substantially more robust than for most alternatives. For the patient who has failed two adequate antidepressant trials and has no contraindications to lithium, this remains the augmentation strategy with the best-established efficacy. Baseline renal function, thyroid function, and calcium should be checked before initiation, with monitoring every 3-6 months once a stable dose is achieved.

Atypical Antipsychotic Augmentation

Aripiprazole (2-10 mg), quetiapine (150-300 mg), and brexpiprazole (1-3 mg) have FDA approval for adjunctive treatment of MDD. Comorbid ADHD should be assessed as it may influence treatment response. The evidence is strongest for aripiprazole augmentation, with NNT of approximately 7-10 for response compared to antidepressant monotherapy.

Choosing Between Agents

The choice among aripiprazole, quetiapine, and brexpiprazole is driven more by side effect profile than by comparative efficacy data, because head-to-head trials between these agents for MDD augmentation are limited. Aripiprazole is generally considered the first choice due to its NNT of 7-10, relatively neutral metabolic profile compared to quetiapine, and well-characterized dose-response relationship. Start at 2 mg daily and titrate based on response and tolerability, typically reaching 5-10 mg. Quetiapine offers the additional benefit of sedation, which can be useful in patients with prominent insomnia or anxiety, but carries greater metabolic risk (weight gain, dyslipidemia, hyperglycemia) that must be monitored. Brexpiprazole has a similar pharmacologic profile to aripiprazole with potentially less akathisia, though the clinical data are less extensive. For all three agents, patients should be counseled about the common side effects — particularly weight gain and akathisia with aripiprazole, and sedation and metabolic effects with quetiapine — and monitored with periodic metabolic panels.